OBJECTIVE: To evaluate the relationship between hormonal contraceptive use and the acquisition of cervical sexually transmitted infections (STI) among HIV-1-infected women. DESIGN: A prospective cohort study of 242 commercial sex workers in Mombasa, Kenya, followed from the time of HIV-1 infection. METHODS: At monthly follow-up visits, sexual behavior and contraceptive use were recorded, and laboratory screening for STI was performed. Multivariate Andersen-Gill proportional hazards models were constructed to examine the association between the use of hormonal contraception and the occurrence of cervical STI. RESULTS: The median duration of follow-up after HIV-1 acquisition was 35 months, and 799 person-years of follow-up were accrued. After adjustment for demographic factors and sexual behavior, women using the injectable contraceptive depot medroxyprogesterone acetate were at increased risk of Chlamydia trachomatis infection [hazard ratio (HR) 3.1, 95% confidence interval (CI) 1.0-9.4, P = 0.05] and cervicitis (HR 1.6, 95% CI 1.0-2.3, P = 0.03) compared with women using no contraception. The use of oral contraceptive pills was associated with an increased risk of cervicitis (HR 2.3, 95% CI 1.4-3.8, P = 0.001). Hormonal contraception was not associated with an increased risk of infection with Neisseria gonorrhoeae. CONCLUSION: The use of hormonal contraception by HIV-1-infected women was associated with an increased risk of cervicitis and cervical chlamydia infection. HIV-1-seropositive women using hormonal contraception should be counseled about the importance of consistent condom use to prevent both STI and HIV-1 transmission.
OBJECTIVE: To evaluate the relationship between hormonal contraceptive use and the acquisition of cervical sexually transmitted infections (STI) among HIV-1-infectedwomen. DESIGN: A prospective cohort study of 242 commercial sex workers in Mombasa, Kenya, followed from the time of HIV-1 infection. METHODS: At monthly follow-up visits, sexual behavior and contraceptive use were recorded, and laboratory screening for STI was performed. Multivariate Andersen-Gill proportional hazards models were constructed to examine the association between the use of hormonal contraception and the occurrence of cervical STI. RESULTS: The median duration of follow-up after HIV-1 acquisition was 35 months, and 799 person-years of follow-up were accrued. After adjustment for demographic factors and sexual behavior, women using the injectable contraceptive depot medroxyprogesterone acetate were at increased risk of Chlamydia trachomatis infection [hazard ratio (HR) 3.1, 95% confidence interval (CI) 1.0-9.4, P = 0.05] and cervicitis (HR 1.6, 95% CI 1.0-2.3, P = 0.03) compared with women using no contraception. The use of oral contraceptive pills was associated with an increased risk of cervicitis (HR 2.3, 95% CI 1.4-3.8, P = 0.001). Hormonal contraception was not associated with an increased risk of infection with Neisseria gonorrhoeae. CONCLUSION: The use of hormonal contraception by HIV-1-infectedwomen was associated with an increased risk of cervicitis and cervical chlamydia infection. HIV-1-seropositivewomen using hormonal contraception should be counseled about the importance of consistent condom use to prevent both STI and HIV-1 transmission.
Authors: Chelsea B Polis; Maria J Wawer; Noah Kiwanuka; Oliver Laeyendecker; Joseph Kagaayi; Tom Lutalo; Fred Nalugoda; Godfrey Kigozi; David Serwadda; Ronald H Gray Journal: AIDS Date: 2010-07-31 Impact factor: 4.177
Authors: João P Gomes; William J Bruno; Alexandra Nunes; Nicole Santos; Carlos Florindo; Maria J Borrego; Deborah Dean Journal: Genome Res Date: 2006-11-07 Impact factor: 9.043
Authors: Athena P Kourtis; Lisa Haddad; Jennifer Tang; Lameck Chinula; Stacey Hurst; Jeffrey Wiener; Sascha Ellington; Julie A E Nelson; Amanda Corbett; Kristina De Paris; Caroline C King; Mina Hosseinipour; Irving F Hoffman; Denise J Jamieson Journal: Contemp Clin Trials Date: 2016-11-09 Impact factor: 2.226
Authors: Katherine G Michel; Richard P H Huijbregts; Jonathan L Gleason; Holly E Richter; Zdenek Hel Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731
Authors: Richard P H Huijbregts; E Scott Helton; Katherine G Michel; Steffanie Sabbaj; Holly E Richter; Paul A Goepfert; Zdenek Hel Journal: Endocrinology Date: 2013-01-25 Impact factor: 4.736
Authors: Lisa E Manhart; King K Holmes; James P Hughes; Laura S Houston; Patricia A Totten Journal: Am J Public Health Date: 2007-04-26 Impact factor: 9.308
Authors: Amy Romer; Marcia L Shew; Susan Ofner; Melissa L Gilliam; Summer L Martins; J Dennis Fortenberry Journal: J Adolesc Health Date: 2012-06-05 Impact factor: 5.012